Medication info
Telmitan Plus Tablet 40/12.5 mg

Telmitan Plus Tablet 40/12.5 mg

Prescription medicationTabletOral
Ingredient · strength
Telmisartan›40mg / 1 tabletHydrochlorothiazide›12.5mg / 1 tablet
Manufacturer / importer
Sinphong Pharmaceutical Co., Ltd.
Appearance
Oval-shaped tablet consisting of two layers, white/pink, with possible pink specks on the white layer.
Packaging
30 tablets/box (10 tablets/PTP x 3)
Approval status
Active

MFDS item code 201101834 · Notified 2011.03.31 · Insurance code 648506850

Summary

Main use
Treatment of essential hypertension not adequately controlled with telmisartan alone
Who takes it
Adults · Children
Adult dose
Adults Take once daily with a beverage, with or without food, in patients whose blood pressure is not adequately controlled with telmisartan alone. Before switching to this fixed-dose combination, it is recommended that the doses of each component be adjusted individually according to the patient’s needs. When clinically appropriate, a direct switch from monotherapy to this medicine may also be considered. - The telmisartan/hydrochlorothiazide 40/12.5mg combination may be administered to patients whose blood pressure is not adequately controlled with telmisartan 40mg. - The telmisartan/hydrochlorothiazide 80/12.5mg combination may be administered to patients whose blood pressure is not adequately controlled with telmisartan 80mg. - The telmisartan/hydrochlorothiazide 80/25mg combination may be administered to patients whose blood pressure is not adequately controlled with telmisartan 80mg and hydrochlorothiazide 12.5mg given as separate products or as a combination product. Sodium or volume depletion should be corrected before starting this medicine. Patients with renal impairment No dosage adjustment is necessary in patients with mild to moderate renal impairment. Do not administer this medicine to patients with severe renal impairment (creatinine clearance<30mL/min). Regular monitoring of renal function is recommended. Patients with hepatic impairment This medicine should be administered with caution to patients with mild to moderate hepatic impairment. Do not administer more than 40/12.5mg of this medicine once daily. Do not administer this medicine to patients with severe hepatic impairment (see Precautions for Use, section 2). Thiazide diuretics should be administered with caution to patients with impaired liver function. Elderly patients No dosage adjustment is necessary.
Child dose
The safety and efficacy of this medicine have not been established in children under 18 years of age.

Ingredients

Manufacturer
Sinphong Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of essential hypertension not adequately controlled with telmisartan alone

  • Essential hypertension
View approved original text

This medication is used for patients with essential hypertension who find it difficult to control blood pressure with Telmisartan monotherapy. This drug helps to lower blood pressure more effectively and reduce the risk of cardiovascular complications. It plays an important role in managing the patient's blood pressure, thereby assisting in maintaining a healthy lifestyle.

How to take

Adult dose

Adults Take once daily with a beverage, with or without food, in patients whose blood pressure is not adequately controlled with telmisartan alone. Before switching to this fixed-dose combination, it is recommended that the doses of each component be adjusted individually according to the patient’s needs. When clinically appropriate, a direct switch from monotherapy to this medicine may also be considered. - The telmisartan/hydrochlorothiazide 40/12.5mg combination may be administered to patients whose blood pressure is not adequately controlled with telmisartan 40mg. - The telmisartan/hydrochlorothiazide 80/12.5mg combination may be administered to patients whose blood pressure is not adequately controlled with telmisartan 80mg. - The telmisartan/hydrochlorothiazide 80/25mg combination may be administered to patients whose blood pressure is not adequately controlled with telmisartan 80mg and hydrochlorothiazide 12.5mg given as separate products or as a combination product. Sodium or volume depletion should be corrected before starting this medicine. Patients with renal impairment No dosage adjustment is necessary in patients with mild to moderate renal impairment. Do not administer this medicine to patients with severe renal impairment (creatinine clearance<30mL/min). Regular monitoring of renal function is recommended. Patients with hepatic impairment This medicine should be administered with caution to patients with mild to moderate hepatic impairment. Do not administer more than 40/12.5mg of this medicine once daily. Do not administer this medicine to patients with severe hepatic impairment (see Precautions for Use, section 2). Thiazide diuretics should be administered with caution to patients with impaired liver function. Elderly patients No dosage adjustment is necessary.

Child dose

The safety and efficacy of this medicine have not been established in children under 18 years of age.

Precautions

This medication should not be used during pregnancy, especially in the second and third trimesters, as it can cause serious harm to the fetus. Patients with allergies to any of the components of this medication, or those with certain liver or kidney diseases, as well as pregnant or nursing women, should not take this medication. Elderly patients, those with hyperkalemia, and patients with liver or heart diseases should take this medication with caution, as there is a risk of skin cancer; thus, exposure to sunlight should be avoided and skin condition should be checked regularly. This medication has a blood pressure-lowering effect, and side effects such as dizziness, hypotension, and electrolyte imbalances may occur, particularly when there is a deficiency in fluids or sodium. When taken with other antihypertensives, certain diuretics, lithium, or potassium supplements, side effects may be increased, and it should be taken after consulting a doctor. This medication requires frequent monitoring of fluid and electrolyte status; any abnormal symptoms should be reported to a doctor immediately. Caution is advised when driving or operating machinery, as dizziness or drowsiness may occur. In case of overdose, symptoms such as hypotension, electrolyte imbalances, and dehydration may arise, requiring immediate emergency treatment. Safety and efficacy have not been established for children under 18 years of age.

Side effects

  • Bronchitis
  • pharyngitis
  • sinusitis
  • hypokalemia
  • hyperuricemia
  • hyponatremia
  • anxiety
  • depression
  • insomnia
  • sleep disorders
Show 119 more
  • dizziness
  • syncope
  • paresthesia
  • visual impairment
  • blurred vision
  • vertigo
  • tachycardia
  • arrhythmia
  • hypotension
  • orthostatic hypotension
  • dyspnea
  • chest pain
  • pulmonary inflammation
  • pulmonary edema
  • diarrhea
  • dry mouth
  • bloating
  • abdominal pain
  • constipation
  • dyspepsia
  • vomiting
  • gastritis
  • liver function abnormalities
  • liver disorders
  • angioedema
  • erythema
  • pruritus
  • rash
  • hyperhidrosis
  • urticaria
  • back pain
  • muscle spasm
  • myalgia
  • arthralgia
  • limb pain
  • systemic lupus erythematosus
  • erectile dysfunction
  • chest pain
  • influenza-like illness
  • pain
  • increased blood uric acid
  • increased blood creatinine
  • increased blood creatine phosphokinase
  • elevated liver enzymes
  • upper respiratory tract infection
  • urinary tract infection
  • cystitis
  • sepsis
  • anemia
  • eosinophilia
  • thrombocytopenia
  • anaphylactic reaction
  • hyperkalemia
  • hypoglycemia
  • drowsiness
  • bradycardia
  • cough
  • interstitial lung disease
  • dry mouth
  • abdominal discomfort
  • eczema
  • drug rash
  • toxic skin rash
  • neuropathic pain
  • renal impairment
  • weakness
  • increased blood creatine phosphokinase
  • decreased hemoglobin
  • sialadenitis
  • non-melanoma skin cancer
  • thrombocytopenic purpura
  • hemolytic anemia
  • bone marrow failure
  • leukopenia
  • agranulocytosis
  • hypersensitivity
  • jaundice
  • cholestasis
  • photosensitivity reaction
  • toxic epidermal necrolysis
  • lupus-like syndrome
  • acute renal failure
  • diabetes
  • weakness
  • fever
  • nausea
  • gastrointestinal bleeding
  • esophagitis
  • headache
  • tremor
  • facial flushing
  • malaise
  • fatigue
  • proteinuria
  • pruritus
  • myalgia
  • floating sensation
  • tremor of lips and hands
  • sensory hyperreactivity
  • vision deterioration
  • hypotension
  • tachycardia
  • hypokalemia
  • hypochloremia
  • dehydration
  • muscle cramps
  • nausea
  • somnolence
  • acute respiratory distress syndrome
  • acute angle-closure glaucoma
  • choroidal effusion
  • acute myopia
  • dyspnea
  • fever
  • worsening pulmonary condition
  • hypotension
  • intestinal vascular edema
  • nausea
  • diarrhea

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air and moisture, so it should be stored in a tightly closed container. The recommended storage temperature is between 1 degree and 30 degrees Celsius at room temperature to maintain the medication's effectiveness for a longer time.

Appearance and packaging

Appearance

Oval-shaped tablet consisting of two layers, white/pink, with possible pink specks on the white layer.

Package unit

30 tablets/box (10 tablets/PTP x 3)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.